These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 17059429)
1. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. Colaizzo D; Amitrano L; Tiscia GL; Scenna G; Grandone E; Guardascione MA; Brancaccio V; Margaglione M J Thromb Haemost; 2007 Jan; 5(1):55-61. PubMed ID: 17059429 [TBL] [Abstract][Full Text] [Related]
2. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis. Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908 [TBL] [Abstract][Full Text] [Related]
3. Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation. Grandone E; Colaizzo D; Tiscia GL; Vergura P; Chinni E; Iannaccone L; Antinolfi I; Guardascione MA; Margaglione M Thromb Haemost; 2008 Mar; 99(3):640-2. PubMed ID: 18327418 [No Abstract] [Full Text] [Related]
4. Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis. Yoo EH; Jang JH; Park KJ; Gwak GY; Kim HJ; Kim SH; Kim DK Int J Lab Hematol; 2011 Oct; 33(5):471-6. PubMed ID: 21435189 [TBL] [Abstract][Full Text] [Related]
5. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. De Stefano V; Fiorini A; Rossi E; Za T; Farina G; Chiusolo P; Sica S; Leone G J Thromb Haemost; 2007 Apr; 5(4):708-14. PubMed ID: 17263783 [TBL] [Abstract][Full Text] [Related]
6. JAK2 mutations across a spectrum of venous thrombosis cases. Shetty S; Kulkarni B; Pai N; Mukundan P; Kasatkar P; Ghosh K Am J Clin Pathol; 2010 Jul; 134(1):82-5. PubMed ID: 20551270 [TBL] [Abstract][Full Text] [Related]
7. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation. Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380 [TBL] [Abstract][Full Text] [Related]
15. Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis? Lamy M; Palazzo P; Agius P; Chomel JC; Ciron J; Berthomet A; Cantagrel P; Prigent J; Ingrand P; Puyade M; Neau JP Cerebrovasc Dis; 2017; 44(3-4):97-104. PubMed ID: 28609766 [TBL] [Abstract][Full Text] [Related]
16. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia]. Iványi JL; Marton E; Plander M Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365 [TBL] [Abstract][Full Text] [Related]
17. Mesenteric venous thrombosis secondary to an unsuspected JAK2 V617F-positive myeloproliferative disorder. Bourke MG; Martin ST; O'Dwyer M; Hanaghan J; Bennani F; Barry MK Ir J Med Sci; 2012 Jun; 181(2):285-7. PubMed ID: 19693645 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis. Karaköse S; Oruç N; Zengin M; Akarca US; Ersöz G Turk J Gastroenterol; 2015 Jan; 26(1):42-8. PubMed ID: 25698270 [TBL] [Abstract][Full Text] [Related]